Euro-Med Laboratories Phil., Inc.

EURO

PHY2352T1098

Pharmaceuticals

End-of-day quote Philippines S.E. Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
0.74 ^PHP	-5.13%		-2.63%	-1.33%

Apr. 15	Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Euro-Med Laboratories Phil., Inc. Announces Demise of Atty. Francis Y. Gaw, Member of the Board of Directors

April 22, 2021 at 07:19 pm EDT

Euro-Med Laboratories Phil., Inc. announced demise of one of the members of the Board of Directors, Atty. Francis Y. Gaw on April 22, 2021. He was elected as Director of Euro-Med on August 14, 2020.

Latest news about Euro-Med Laboratories Phil., Inc.

Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 14	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Euro-Med Laboratories Phil., Inc. Declares Cash Dividend, Payable on 27 November 2023	23-10-24	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-18	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-13	CI
Euro-Med Laboratories Phil., Inc. Approves Cash Dividend, Payable on 21 November 2022	22-10-18	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-14	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-10	CI
Euro-Med Laboratories Phil., Inc. Approves Declaration of Cash Dividend as of 31 December 2020, Paid on 24 January 2022	21-12-21	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Euro-Med Laboratories Phil., Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI
Euro-Med Laboratories Phil., Inc. Appoints Mr. Anthony Joseph Y. Gaw as Director	21-06-16	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-29	CI
Euro-Med Laboratories Phil., Inc. Announces Demise of Atty. Francis Y. Gaw, Member of the Board of Directors	21-04-22	CI
Euro-Med Laboratories Phil., Inc. Announces Resignation of Michael Vincent Y. Yap as Vice President	21-03-30	CI
Euro-Med Laboratories Phil., Inc. Elects Mr. Enrique Y. Yap, Jr. as Director	20-08-18	CI
Euro-Med Laboratories Phil., Inc. Declares Cash Dividend, Payable on 08 September 2020	20-07-28	CI
Euro-Med Laboratories Phil., Inc. Provides Earnings Guidance for the Year 2020	20-06-30	CI
Euro-Med Laboratories Phil., Inc. Announces Parent Earnings Results for the First Quarter Ended March 31, 2020	20-06-30	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-06-28	CI
Euro-Med Laboratories Phil., Inc. Approves Resignation of Michael Vincent Y. Yap as Director and Assistant Corporate Secretary and Retirement of Rnold D. Ong as Senior Vice President	19-11-26	CI
Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-13	CI

Chart Euro-Med Laboratories Phil., Inc.

Duration

Period

More charts

Euro-Med Laboratories Phil., Inc. is a Philippines-based company, which is engaged in the manufacturing of pharmaceutical products, such as large and small-volume parenteral and other solutions, inhalation, irrigation, and dialysis. It also manufactures sterile water for injection, and other solutions, such as ophthalmic, inhalation, irrigation and dialysis. The Company's segments include manufacturing pharmaceutical products, providing health and other care services, and development and operation of quick service restaurants. Its subsidiaries include Hemotek Renal Center, Inc. (Hemotek), and CafeFrance Corp (CafeFrance). Hemotek provides renal and other healthcare services and is engaged as a dialysis center. CafeFrance is engaged in the development and operation of quick service restaurant (QSR). CafeFrance is engaged in operating restaurants, bakeries, food services, catering, food production and other related services incidental thereto.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
EURO-MED LABORATORIES PHIL., INC.	-1.33%	56.01M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.40%	44.1B
OTSUKA HOLDINGS CO., LTD.	+17.11%	21.97B
CIPLA LIMITED	+8.10%	13.27B
SANDOZ GROUP AG	+6.06%	13.22B
ZYDUS LIFESCIENCES LIMITED	+35.95%	11.36B
ONO PHARMACEUTICAL CO., LTD.	-8.53%	7.07B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+7.71%	5.23B